New antiepileptic drugs

Journal of Clinical Neuroscience

Volumn 7, Issue 2, 2000, Pages 88-101

  Vajda, F J E ^a  

^a ST VINCENT S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; FELBAMATE; GABAPENTIN; GABATRIL; LAMOTRIGINE; OXCARBAZEPINE; TIAGABINE; TOPIRAMATE; VIGABATRIN; ZONISAMIDE;

ADOLESCENT; ADULT; ANTICONVULSANT THERAPY; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG EFFICACY; DRUG MECHANISM; EPILEPSY; FATIGUE; HUMAN; HUMAN CELL; HUMAN TISSUE; INFANT; META ANALYSIS; MULTICENTER STUDY; PRIORITY JOURNAL; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; VISUAL FIELD DEFECT;

EID: 0033912030     PISSN: 09675868     EISSN: None     Source Type: Journal    
DOI: 10.1054/jocn.1999.0157     Document Type: Review

References (270)

1. Lippert B., Metcalf B., Jung M. J., Casara P. 4-amino-hex-5-enoic acid, a selective catalytic inhibitor of 4-aminobutyric acid aminotransferase in mammalian brain. Eur J Biochem. 74:1977;441-445.
2. Schechter P. J., Trainer Y., Grove J. Attempts to correlate alterations in brain GABA metabolism by GABA-T inhibitors with their anticonvulsant effects. Mandel P., DeFeudes F. V. GABA-biochemistry and CNS Functions. 1979;43-57 Plenum Press, New York.
3. Haegele K. D., Schechter P. J. Kinetics of the enantiomers of vigabatrian after an oral dose of the racemate or the active S-enantiomer. Clin Pharmac Ther. 40:1986;581-586.
4. Haegele K. D., Huebert N. D., Ebel M. Pharmacokinetics of vigabatrin: implications of creatinine clearance. Clin Pharm Therap. 44:1988;558-565.
5. Saletu B., Grunberger J., Linzmayer L. Psychophysiological and psychometric studies after manipulating the GABA system by vigabatrin, a GABA transaminase inhibitor. Intern J Psychophysiol. 4:1986;63-80.
6. Richens A. Pharmacology and clinical pharmacology of vigabatrin. J Child Neurology. 6:1991;2S7-2S10.
7. Mumford J. P. A profile of vigabatrin. Br J Clin Pract. 42 (suppl 61):1988;7-9.
8. Ben-Menachem E., Persson L., Schechter P. J. Effects of single doses of vigabatrin on CSF concentrations of GABA, homocarnosine, homovanillic acid and 5-hydroxyindoleacedic acid in patients with complex partial seizures. Epilepsy Res. 2:1988;96-101.
9. Ben-Menachem E., Persson L. I., Mumford J. P. Effect of long term vigabatrin therapy on selected CSF neurotransmitter concentrations. J Child Neurology. 6 (suppl 2):1991;11-16.
10. Grant S. M., Heel R. C. vigabatrin: A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in epilepsy and disorders of motor control. Drugs. 4:1991;889-926.
11. Gram L., Klosterskov P., Dam M. Gamma-vinyl GABA: A double-blind, placebo-controlled trial in partial epilepsy. Ann Neurol. 17:1985;262-266.
12. Rimmer E. M., Richens A. double-blind study of gamma-vinyl GABA in patients with refractory epilepsy. Lancet 1. (8370):1984;189-190.
13. Loiseau P., Hardenberg J. P., pestre M. Double-blind, placebo-controlled study of vigabatrin (gamma-vinyl GABA) in drug resistant epilepsy. Epilepsia. 27:1986;115-120.
14. Tassinari C. A., Michelucci R., Ambroseetto G. Double-blind study of vigabatrin in the treatment of drug resistant epilepsy. Arch Neurol. 44:1987;907-910.
15. Tartara A., Manni A., Galimberti C. A. Vigabatrin in the treatment of epilepsy: a double-blind placebo controlled study. Epilepsia. 27:1986;717-723.
16. Remy C., Favel P., Tell G. Double-blind, placebo-controlled, crossover study of vigabatrin in drug resistant epilepsy of the adult. Boll Lega Ital Epil. 54/55:1986;241-243.
17. French J. A., Mosier M., Walker K., Sommerville K., Sussman N. A double-blind, placebo-controlled study of vigabatrin three g/day in patients with uncontrolled complex partial seizures. Neurology. 46:1996;54-61.
18. Penry J. K., Wilder B. J., Sachdeo R. C. Multicenter dose-response study of vigabatrin in adults with focal (partial) epilepsy. Epilepsia. 34 (suppl 6):1993;67.
19. Beran R. G., Berkovic S. F., Buchanan N., Danta G., Mackenzie R., Schapel G., Sheean G., Vajda F. A double-blind, placebo-controlled cross-over study of vigabatrin 2g/day and 3 g/day in uncontrolled partial seizures. Seizure. 5:1996;259-265.
20. Appleton R. Vigabatrin in the management of generalized seizures in children. Seizures. 4:1995;45-48.
21. Arzimanoglou A. A., Dumas C., Ghirardi L. Multicentre clinical evaluation of vigabatrin (Sabril) in mild to moderate partial epilepsies. Seizure. 6:1997;225-231.
22. Michelucci R., Tassinari C. A. Response to vigabatrin in relation to seizure type. Br J Clin Pharmacol. 27 (suppl 1):1989;119S-12S.
23. Lortie A., chiron C., Mumford J., Dulac O. The potential for increasing seizure frequency, relapse, and appearance of new seizure types with vigabatrin. Neurology. 43:1993;S24-27.
24. Feucht M., Brantner-Inthaler S. Gamma-vinyl GABA (vigabatrin) in the therapy of Lennox-Gastaut Syndrome: an open study. Epilepsia. 35:1994;993-998.
25. Herranz J. L., Arteaga R., Farr I. N. Dose-response study of vigabatrin in children with refractory epilepsy. J Child Neurol 6 suppl. 2:1991;S45-S51.
26. de Bittencourt P. R. M., Mazer S., Marcourakis T., Bigarella M. M., Ferreira Z. S., Mumford J. P. Vigabatrin: Clinical evidence supporting rational polytherapy in management of uncontrolled seizures. Epilepsia. 35:1994;373-380.
27. Kalviainen R., Aikia M., Saukkonen A. M. Vigabatrin versus carbamazepine monotherapy in patients with newly diagnosed epilepsy. A randomised controlled study. Arch Neurol. 52:1995;989-996.
28. Tanganelli P., Regesta G. Vigabatrin vs. carbamazepine monotherapy in newly diagnosed epilepsy: a randomized response conditional cross-over study. Epilepsy Res. 25:1996;257-262.
29. Chiron C., Dumas C., Jambaque I., Mumford J., Dulac O. Randomized trial comparing vigabatrin and hydrocortisone in infantile spasms due to tuberous sclerosis. Epilepsy Res. 26:1997;389-395.
30. Livingston J. H., Beaumont D., Arzimanoglou A., Aicardi J. Vigabatrin in the treatment of epilepsy in children. Br J clin Pharm. 27 (suppl 1):1989;109S-112S.
31. Luna D., Dulac O., Pajot N., Beaumont D. Vigabatrin in the treatment of childhood epilepsies. A single-blind placebo controlled study. Epilepsia. 30:1989;430-437.
32. Chiron C., Dulac O., Beaumont D. Therapeutic trial of vigabatrin in refractory infantile spasms. J Child Neurol. 6 (suppl 2):1991;S52-S59.
33. Vigevano F., Cilio M. R. Vigabatrin versus ACTH as first-line treatment for infantile spasms: a randomized, prospective study. Epilepsia. 38:1997;1270-1274.
34. Browne T. R., Mattson R. H., Penry J. K. Vigabatrin for refractory complex partial seizures. Multicenter single-blind study and long-term follow-up. Neurology. 37:1987;184-189.
35. Dijkstra J. B., McGuire A. M., Trimble M. R. the effect of vigabatrin on cognitive function and mood. Hum Psychopharmacol. 7:1992;329-323.
36. Dodrill C. B., Arnett J. L., Sommerville K. W., Sussman N. M. Evaluation of the effects of vigabatrin on cognitive abilities and quality of life. Neurology. 43:1993;2501-2507.
37. Gruenewald R. A., Thompson P. J., Corcoran R. Effects of vigabatrin on partial seizures and cognitive function. J Neurol Neurosurg Psych. 57:1994;1057-1063.
38. Provinciali L., Bartolini M., Mari F. Influence of vigabatrin on cognitive performances and behaviour in patients with drug resistant epilepsy. Acta neurol Scand. 94:1996;12-18.
39. Sander J. W. A. S., Hart Y. M. Vigabatrin and behavior disturbances. Lancet. 335:1990;57.
40. Sander J. W. A. S., Hart Y. M., Trimble M. R., Shorvon S. D. Behavioral disturbances associated with vigabatrin therapy. Epilepsia. 32 (suppl 1):1991;12.
41. Matsuo F., Bergen D., Faught E., Messenheimer J. A. Placebo-controlled study of efficacy and safety of lamotrigine in patients with partial seizures. neurology. 43:1993;2284-2291.
42. Wolf P. The use of antiepileptic drugs in epileptology with respect to psychiatry. Neuropsychobiol. 27:1993;127-131.
43. Cockerell C., Moriaty J., Trimble M. R., Shorvon S. D., Sander J. W. A. S. Epidemiological survey of acute psychological disorders in epilepsy. epilepsy Res. 25:1996;119-131.
44. Eke T., Talbot J. F., Lawden M. C. Severe persistent visual field constriction associated with vigabatrin. BMJ. 314:1997;180-181.
45. Wilson E. A., Brodie M. J. Severe persistent visual field constriction associated with vigabatrin. Brit Med J. 314:1997;1693.
46. Harding G. F. A. Abnormal visual fields associated with vigabatrin. Brit Med J. 314:1997;1394.
47. Harding G. F. A. Severe persistent visual field constriction associated with vigabatrin. Brit Med J. 316:1998;232-233.
48. Rao G. P., Fat A. F., Kyle G., Leach J. P., Chadwick D. W., Batterbury M. Study is needed of visual field defects associated with any long term antiepileptic drugs. Brit med J. 317:1998;206.
49. Kälviäinen, R. Nousiainen, I. Nikoskelainen, E. Partanen, J. Partanen, K. Mantyjarvi, M. Riekkinen, P. J. Abstract. Proc. International Congress, European Epilepsy Society, Warsaw, 1998.
50. Krauss G. L., Mary A. J., Miller N. R. Vigabatrin-associated retinal cone system dysfunction. Neurology. 50:1998;614-618.
51. Ben-Menachem E., Persson L. I., Schechter P. J., Haegele K. D., Huebert N., Hardenberg J., Dahlgren L., Mumford J. P. The effect of different vigabatrin treatment regimens on CSF biochemistry and seizure control in epileptic patients. Br J Clin Pharmac. 1989.
52. Cheung H., Kamp D., Harris E. An in vitro investigation of the action of lamotrigine on neuronal voltage-activated sodium channels. Epilepsy Res. 13:1992;107-112.
53. Lang D. G., Wang C. M., Cooper B. R. Lamotrigine, phenytoin and carbamazepine interactions on the sodium current present in N4TG1 mouse neuroblastoma cells. J Parmacol Exp Ther. 266:1993;829-835.
54. Leach M. J., Marden C. M., Miller A. A. Pharmacological studies on lamotrigine, a novel potential antiepileptic drug: II. Neurochemical studies on the mechanism of action. Epilepsia. 27:1986;490-497.
55. Meldrum B. S. Excitatory amino acids in epilepsy and potential novel therapies. Epilep Res. 12:1992;189-196.
56. Meldrum B. S. The role of glutamate in epilepsy and other CNS disorders. Neurology. 44(11 Suppl 8):1994;S14-23.
57. Meldrum B. S., Leach M. The mechanism of action of lamotrigine. Rev Contemp Pharmacother. 5:1994;107-114.
58. rogawski M. A., Porter R. J. Antiepileptic drugs: pharmacological mechanisms and clinical efficacy with consideration of promising developmental stage compounds. Pharmacol Rev. 42:1990;223-286.
59. McGeer E. G., McGeer P. L. Some factors influencing the neurotoxicity of intrastriatal injections of kainic acid. Neurochem Res. 3:1978;501-517.
60. Miller A. A., Sawyer D. A., Roth B., Meldrum B. S. Lamotrigine. New anticonvulsant drugs. 1986;John Libbey, London. p. 165-77.
61. Miller A. A., Wheatley P., Sawyer D. A. Pharmacological studies on lamotrigine, a novel potential antiepileptic drug: I. Anticonvulsant profile in mice and rats. Epilepsia. 27:1986;483-489.
62. Binnie C. D., Debets R. M. C. Double-blind crossover trial of lamotrigine (lamictal) as add-on therapy in intractable epilepsy. Epilep Res. 4:1989;222-229.
63. Jawad S., Richens A., Goodwin G. Controlled trial of lamotrigine (Lamictal) for refractory partial seizures. Epilepsia. 30:1989;356-363.
64. Hamilton M. J., Cohen A. F., Yuen A. W. C. Carbamazepine and lamotrigine in healthy volunteers: relevance to early tolerance and clinical trial dosage. Epilepsia. 34:1993;166-173.
65. Rambeck B., Wolf P. Lamotrigine clinical pharmacokinetics. Clin Pharmacokinet. 25:1993;433-443.
66. Dickins M., Sawyer D. A., Morley T. J., Levy R. H., Mattson R. H., Meldrum B. S. Lamotrigine: chemistry and biotransformation. Antiepileptic Drugs. 4th ed. 1995;Raven Press Ltd. new York. p. 871-5.
67. Parsons D. N., Dickins M., Morley T. J., Levy R. H., Mattson R. H., Meldrum B. S. Lamotrigine: absorption, distribution and excretion. Antiepileptic Drugs. 4th ed. 1995;Raven Press Ltd. New York. p. 877-81.
68. Bialer M. Comparative pharmacokinetics of the newer antiepileptic drugs. Clin Pharmacokinet. 24:1993;441-452.
69. Yuen A. W. C., Peck A. W. Lamotrigine pharmacokinetics: oral and i.v. infusion in man. Br J Clin Pharmacol. 26:1988;242P.
70. Yuen A. W. C., Land G., Weatherley B. C. Sodium valproate acutely inhibits lamotrigine metabolism. Br J Clin Pharmacol. 33:1992;511-513.
71. Jawad S., Yuen W. C., Peck A. W. Lamotrigine: single-dose pharmacokinetics and initial 1 week experience in refractory epilepsy. Epilep Res. 1:1987;194-201.
72. Posner J., Holdich T., Crome P. comparison of lamotrigine pharmacokinetics in young and elderly healthy volunteers. Pharm Med. 1:1991;121-128.
73. Loiseau P., Yuen A. W. C., Duche B. A randomised double-blind placebo-controlled crossover add-on trial of lamotrigine in patients with treatment-resistant partial seizures. Epilep Res. 7:1990;136-145.
74. Matsuo F., Bergen D., Faught E. Placebo-controlled study of the efficacy and safetyof lamotrigine in patients with partial seizures. Neurology. 43:1993;2284-2291.
75. Messenheimer J., Ramsay R. E., Willmore L. J. Lamotrigine therapy for partial seizures: a multicenter, placebo-controlled, double-blind, cross-over trial. epilepsia. 35:1994;113-121.
76. Sander J. W. A. S., Patsalos P. N., Oxley J. R. A randomised double-blind placebo-controlled add-on trial of lamotrigine in patients with severe epilepsy. Epilep Res. 6:1990;221-226.
77. Schapel G. J., Beran R. G., Vajda F. J. E. Double-blind, placebo controlled, crossover study of lamotrigine in treatment resistant partial seizures. J Neurol Neurosurg Psychiatry. 56:1993;448-453.
78. Schmidt D., Ried S., Rapp P. Add-on treatment with lamotrigine for intractable partial epilepsy: a placebo-controlled cross-over trial [abstract]. Epilepsia. 34 (Suppl. 2):1993;66.
79. Smith D., Baker G., Davies G. Outcomes of add-on treatment with lamotrigine in partial epilepsy. Epilepsia. 34:1993;312-322.
80. Stolarek I., Blacklaw J., Forrest G. Vigabatrin and lamotrigine in refractory epilepsy. J Neurol Neurosurg Psychiatry. 57:1994;921-924.
81. Yuen A. W. C. Lamotrigine: a review of antiepileptic efficacy. Epilepsia. 35 (Suppl 5):1994;33-36.
82. Smith D., Chadwick D., Baker G. Seizure severity and the quality of life. Epilepsia. 34 (Suppl 5):1993;S31-35.
83. Ferrie C. D., Robinson R. O., Knott C. Lamotrigine as an add-on drug in typical absence seizures. Acta Neurol Scand. 91:1995;200-202.
84. Manonmani V., Wallace S. J. Epilepsy with myoclonic absences. Arch Dis Child. 70:1994;288-290.
85. Timmings P. L., Richens A. Lamotrigine in primary generalised epilepsy. Lancet. 339:1992;1300-1301.
86. Sander J. W. A. S., Hart Y. M., Patsalos P. N. Lamotrigine and generalised seizures [abstract]. Epilepsia. 32 (Suppl. 1):1991;59.
87. Stewart J., Hughes E., Reynolds E. H. Lamotrigine for generalised epilepsies [letter]. Lancet. 340:1992;1223.
88. Folleti G., Volanschi D. Influence of lamotrigine addition on computerized background EEG parameters in severe epileptogenic encephalopathies. Eur Neurol. 34 (Suppl. 1):1994;87-89.
89. Oller L. F. V., Russi A., Oller D. L. Lamotrigine in the Lennox-Gastaut syndrome [abstract]. Epilepsia. 32 (Suppl. 1):1991;58.
90. Timmings P. L., Richens A. Lamotrigine as an add-on drug in the management of Lennox-Gastaut syndrome. Eur Neurol. 32:1992;305-307.
91. Foletti G., Schmidt M., Delisle M. C. An open study on effectiveness of lamotrigine in the treatment of secondary bilateral synchrony, unsatisfactorily controlled by conventional drugs [abstract]. J Neurology. 239 (Suppl. 2):1992;S71.
92. Motte J., Trevathan E., Arvidsson J. F., Barrera M. N., Mullens E. L., Manasco P. Lamotrigine for generalized seizures associated with the Lennox-Gastaut syndrome. Lamictal Lennox-Gastaut Study Group. N Engl J med. 337:1997;1807-1812.
93. Hosking G., Spencer S., Yuen A. W. C. Lamotrigine in children with severe developmental abnormalities in a pediatric population with refractory seizures [abstract]. Epilepsia. 34 (Suppl. 6):1993;42.
94. Yuen A. W. C., Rafter J. E. W. Lamotrigine (lamictal) as add-on-therapy in pediatric patients with treatment-resistant epilepsy: an overview [abstract]. Epilepsia. 33 (Suppl 3):1992;82-83.
95. Schlumberger E., Chavez F., Palacios L. Lamotrigine in treatment of 120 children with epilepsy. Epilepsia. 35:1994;359-367.
96. Hosking G., Spencer S. C. Lamotrigine as add-on therapy in pediatric patients with treatment-resistant epilepsy: an overview [abstract]. Epilepsia. 34 (Suppl. 2):1993;66.
97. Veggiotti P., Cieuta C., Rey E. Lamotrigine in infantile spasms. Lancet. 344:1994;1375-1376.
98. Dulac O., Withers R. M., Yuen A. W. C. Add-on lamotrigine in pediatric patients with treatment-resistant epilepsy [abstract]. Epilepsia. 32 (Suppl. 1):1991;95.
99. Gibbs J., Appleton R. E., Rosenbloom L. Lamotrigine for intractable childhood epilepsy - a preliminary communication. Dev Med Child Neurol. 34:1992;369-371.
100. Wallace S. J. Add-on open trial of lamotrigine in resistant childhood seizures [abstract]. Brain Dev. 12:1990;734.
101. Battino D., Buti d, Croci D. Lamotrigine in resistant childhood epilepsy. Neuropediatrics. 24:1993;332-336.
102. Mims J., ritter F. J., Dren A. T. Compassionate plea use of lamotrigine in children with incapacitating and/or life-threatening epilepsy [abstract]. Epilepsia. 33 (Suppl. 3):1992;83.
103. Uldall P., Sommer B. Lamotrigine in children: best in generalized epilepsy? [abstract]. Epilepsia. 35 (Suppl. 7):1994;61.
104. Yuen A. W.C. Lamotrigine vs carbamazepine as monotherapy in patients with newly diagnosed or recurrent epilepsy [abstract]. Epilepsia. 35 (Suppl. 8):1994;31.
105. Steiner T. J., Silveira C., Yuen A. W. C. Comparison of lamotrigine (Lamictal) and phenytoin monotherapy in newly diagnosed epilepsy [abstract]. Epilepsia. 35 (Suppl. 7):1994;61.
106. Brodie M. J., Richens A., Yuen A. W. C. Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet. 345:1995;476-479.
107. Richens A. Safety of lamotrigine. Epilepsia. 35 (Suppl. 5):1994;37-40.
108. D'Arcy P. F. Adverse drug reaction profile of lamotrigine. Int Pharm J. 7:1993;140-141.
109. Schachter S., Leppik I., Matsuo F. A multicenter, placebo-controlled evaluation of the safety of lamotrigine (Lamictal) as add-on therapy in outpatients with partial seizures [abstract]. Epilepsia. 33 (Suppl. 3):1992;119.
110. Makin A. J., Fitt S., Williams R. Fulminant hepatic failure induced by lamotrigine. BMJ. 311:1995;292.
111. Pellock J. M. The clinical efficacy of lamotrigine as an antiepileptic drug. Neurology. 44 (Suppl. 8):1994;29-35.
112. Buckley N. A., Whyte I. M., Dawson A. H. Self-poisoning with lamotrigine [letter]. Lancet. 342:1993;1552-1553.
113. Harchelroad F., Lang D., Valeriano J. Lamotrigine overdose. Vet Hum Toxicol. 36:1994;372.
114. Blankenhorn V., Hoffman H. G., Polatschek B. Acute intoxication with the new antiepileptic drug lamotrigine in a suicide attempt. (In German). Epilepsia. 91:1992;473-475.
115. Richens A., Levy R. H., Mattson R. H., Meldrum B. S. Lamotrigine: toxicity. Antiepileptic Drugs. 4th ed. 1995;Raven Press Ltd. New York. p. 897-902.
116. Posner J., Webster H., Yuen W. C. Investigation of the ability of lamotrigine, a novel antiepileptic drug, to induce mixed function oxygenase enzymes [abstract]. Br J Clin Pharmacol. 32:1991;658P.
117. 3H]-gabapentin binding to a novel site in rat brain, homogenate binding studies. Eur J Pharmacol. 244:1993;293-301.
118. 2delta subunit of a Ca++ channel. J Biol Chem. 271:1996;5768-5776.
119. Kocsis J. D., Honmou O. Gabapentin increases GABA-induced depolarization in rat neonatal optic nerve. Neurosci Lett. 169:1994;181-184.
120. Taylor C. P. Mechanism of action of new anti-epileptic drugs. Chadwick D. New trends in epilepsy management: the role of gabapentin. 1993;pp 13-40 Royal Socty of Medicine Services Limited, London.
121. Bartoszyk G. D., Fritschi E., Herrmann M., Satzinger G. Indications for an involvement of the GABA-system in the mechanism of action of gabapentin. Naunyn-Schmiedeberg's Arch Pharmacol. 1983;322 R94.
122. Richens A. Clinical pharmacokinetics of gabapentin. Chadwick D. New trends in epilepsy management: the role of gabapentin. 1993;41-46 Royal Society of Medicine Services, London.
123. Schmidt B. Potential antiepileptic drugs: gabapentin. Levy R. H., Dreifuss F. E., Mattson R. H., Meldrum B. S., Penry J. K. Antiepileptic drugs. 1989;925-935 Raven Press, 3rd edition New York.
124. Tïrck D., Vollmer K. O., Bockbrader H. N., Sedman A. Dose-linearity of the new anticonvulsant gabapentin after multiple oral doses. Eur J Clin Pharmacol. 36:1989;A310.
125. McLean M. J. Gabapentin. Epilepsia. 36 (Suppl. 2):1995;S73-S85.
126. McLean M. J. Clinical pharmacokinetics of gabapentin. Neurology. 44 (Suppl. 5):1994;S17-S22.
127. Haltenson C. E., Keane W. F., Türck D., Bockbrader H. N., Eldon M. A. Disposition of gabapentin (GAB) in hemodialysis (HD) patients [abstract]. Journal of Clinical Pharmacology. 32:1992;751.
128. Foot M., Wallace J. Gabapentin. Pisani F., Perucca E., Avanzani G., Richens A. New antiepileptic drugs. 1991;109-114 Elsevier, Amsterdam:
129. Ojemann L. M., Friel P. H., Ojemann G. A. Gabapentin concentration in human brain [abstract]. Epilepsia. 29:1988;694.
130. Crawford P., Ghadiali E., Lane R., Blumhardt I., Chadwick D. Gabapentin as an antiepileptic drug in man. J Neurol Neurosurg Psychiatry. 50:1987;682-686.
131. Bauer G., Bechinger D., Castell X., Deisenhammer E., Egli M., Klingler D., Kugler J., Ladurner J., Lohoda G., Mamoli F., Schmidt B., Spatz R., Wieser H. G. Gabapentin in the treatment of drug-resistant epileptic patients. Manelis J., Bental E., Loeber J. N., Dreifuss F. E., XV11th Epilepsy International Symposium. Advances in epileptology. 1989;219-221 Raven Press, New York.
132. Sivenius J., Kïlviïinen R., Ylinen A., Riekkinen P. Double blind study of gabapentin in the treatment of partial seizures. Epilepsia. 32:1991;539-542.
133. Lancet. 335:1990;1114-1117.
134. US Gabapentin Study Group No 5. Gabapentin as add-on therapy in partial epilepsy: a double-blind, placebo controlled, parallel-group study. Neurology. 43:1993;2292-2298.
135. Anhut H., Ashman P., Feuerstein T. J., Sauermann W., Saunders M., Schmidt B. Gabapentin (Neurontin) as add-on therapy in patients with partial seizures: a double-blind, placebo-controlled study. The International Gabapentin Study Group. Epilepsia. 35:1994;795-801.
136. Ojemann L. M., Wilensky A. J., Temkin N. R., Chmelir T., Ricker R. A., Wallace J. Long-term treatment with gabapentin for partial epilepsy. Epilepsy Res. 13:1992;159-165.
137. Roberts A., Rieger M., LaMoreaux L., Pierce M. W. Effect of gabapentin (Neurontin) on seizure days and seizure-free intervals [abstract]. Epilepsia. 35 (Suppl. 7):1994;69.
138. Garofalo E., Leiderman D., Chadwick D., Sauermann W., Pierce M. Gabapentin (Neurontin) add-on therapy in patients with generalized epilepsy [abstract]. Epilepsia. 35 (Suppl. 7):1994;61.
139. Fischer J. H., Barr A. N., Rogers S. L., Fischer P. A., Trudeau V. L. Lack of serious toxicity following gabapentin overdose. Neurology. 44:1994;982-983.
140. Zasshi Y. I. Anticonvulsant activities and properties of topiramate. J Yonago Med Assoc. 42:1991;330-346.
141. Nakatsuka T., Komatsu T., Fujii T. Axial skeletal malformations induced by acetazolamide in rabbits. Teratology. 45:1992;629-636.
142. Edmonds H. L. Jr, Jiang D., Zhang Y. P. Topiramate in a rat model of post traumatic epilepsy. Epilepsia. 33 (Suppl. 1):1991;15.
143. Coulter D. A., Sombati S., DeLorenzo R. J. Selective effects of topiramate on sustained repetitive firing and spontaneous bursting in cultured hippocampal neurons. Epilepsia. 34 (Suppl2):1993;123.
144. Brown S. D., Wolf H. H., Swinyard E. D., Twyman R. E., White H. S. The novel anticonvulsant topiramate enhances GABA-mediated chloride flux. Epilepsia. 34 (Suppl 2):1993;122-123.
145. White H. S., Brown S. D., Skeen G. A., Wolf H. H., Twyman R. E. The anticonvulsant topiramate displays a unique ability to potentiate GABA-evoked currents. Epilepsia. 36 (Suppl. 3):1995;39-40.
146. Doose D. R., Gisclon L. G., Stellar S. M., Riffitis J. M., Hills J. F. The effect of food on the biavailability of topiramate from 100-and 400-mg tablets in healthy male subjects. Epilepsia. 33 (Suppl 3):1992;105.
147. Reife R. A. The treatment of epilepsy. Shorvon S. D., Dreifuss F., Fish D., Thomas D. Topiramate: a novel antiepileptic agent. 1996;471-481 Blackwell Science, Oxford.
148. Doose D. R., Walker S. A., Sachdeo R., Kramer L. D., Nayak R. K. Steady-state pharmacokinetics of Tegretol (carbamazepine) and Topomax (topiramate) in patients with epilepsy on monotherapy and during combination therapy. Epilepsia. 35 (Suppl. 8):1994;54.
149. Gisclon L. G., Curtin C. R., Kramer L. D. A comparative study of the steady-state pharmacokinetics of phenytoin (Dilantin Kapseals brand) and of topiramate (Topamax) in male and female epileptic patients on monotherapy and during combination therapy. Pharm Res. 22 (Suppl):1994;S445.
150. Sharief M., Viteri C., Ben-Menachem E. Double-blind, placebo-controlled study of topiramate in patients with refractory partial epilepsy. Epilep Res. 25:1996;217-224.
151. Rosenfeld W., Abou-Khalil B., Morrell M. Double-blind placebo controlled trial of topiramate adjunctive therapy for partial-onset epilepsy [abstract]. Epilepsia. 37 (Suppl. 4):1996;5.
152. Tassinari C. A., Michelucci R., Chauvel P. Double-blind, placebo-controlled trial of topiramate (600 mg daily) for the treatment of refractory partial epilepsy. Epilepsia. 37:1996;763-768.
153. Faught E., Wilder B. J., Ramsay R. E. Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 200-, 400-, and 600-mg daily dosages. Neurology. 46:1996;1684-1690.
154. Privitera M., Fincham R., Penry J. Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 600-, 800-, and 1,000-mg daily dosages. Neurology. 46:1996;1678-1683.
155. Ben Menachem E., Henriksen O., Dam M. Double-blind, placebo-controlled trial of topiramate as add-on therapy in patients with refractory partial seizures. Epilepsia. 37:1996;539-543.
156. Reife R., Pledger G., Lim P. Topiramate: poooled analysis of six placebo-controlled trials [abstract]. Epilepsia. 37 (Suppl.4):1996;74.
157. Bourgeois, B. F. D. Topiramate as adjunctive therapy in partial-onset seizures: the spectrum from adults to children. AED News June 29: 1. Symposium in conjunction with 22nd International Epilepsy Congress Dublin.
158. Sachdeo R. C., Reife R. A., Lim P. Topiramate monotherapy for partial onset seizures. Epilepsia. 38:1997;294-300.
159. Biton V., Montouris G. D. Topiramate double-blind trial in patients with generalised tonic-clonic seizures non-focal origin [abstract]. Epilepsia. 38 (Suppl 3):1997;59.
160. Brodie, M. J. Generalized tonic-clonic seizures and the spectrum of associated seizures in generalised epilepsy: responsiveness to topiramate. AED News June 29: 4. Symposium in conjunction with 22nd International Epilepsy Congress Dublin.
161. Montouris, G. D. Biton, V. Topiramate YTC Study Team. Long-term topiramate therapy in generalised seizures of non-focal origin [abstract]. Epilepsia, 38 (Suppl. 3), 82.
162. Glauser T. A., Sachdeo R. C., Ritter F. J. Topiramate in Lennox Gastaut-syndrome: a double-blind trial [abstract]. Neurology. 48:1997;1729.
163. Glauser T. Expanding the options of Lennox-Gastaut syndrome: efficacy and tolerability of topiramate. AED News June 29: 3. Symposium in conjunction with 22nd International Epilepsy Congress. 1997.
164. Kamin M., Dodson W. E., Shorvon S. D. Tolerability and safety of topiramate. Topiramate: Pharmacokinetics efficacy and tolerability. 1995;Royal Society of Medicine Press, London. p. 23-26.
165. Shorvon S. D. Safety of topiramate: adverse events and relationships to dosing. Epilepsia. 37 (Suppl. 2):1996;S18-22.
166. Wasserstein A., Reife R., Rak I. Tomiramate and nephrolithiasis. Epilepsia. 36 (Suppl. 3):1995;S153.
167. Besag F. M. C., Berry D., Pool F. The relationship between topiramate dose, serum concentration, efficacy and toxicity in teenage and young adult patients [abstract]. Epilepsia. 38 (Suppl. 3):1997;93.
168. Langtry H. D., Gillis J. C., Davis R. Topiramate. Drugs. 54:1997;752-773.
169. Rosenfeld W. E., Doose D. R., Walker S. A. Effect of topiramate on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl estradiol in patients with epilepsy. Epilepsia. 38:1997;317-323.
170. Shorvon S. D., Dodson W. E., Shorvon S. D. Summary. Topiramate: pharmacokinetics, efficacy and tolerability. 1996;The Royal Society of Medicine Press, London. p. 44.
171. Borden L. A., Dhar T. G. M. Tiagabine, SK&F 89976-A, CI-966, and NNC-711 are selective for the cloned GABA transporter GAT-1. Eur J Pharmacol. 269:1994;219-224.
172. Suzdak P. D., Jansen J. A. A review of the preclinical pharmacology of tiagabine: a potent and selective anticonvulsant GABA uptake inhibitor. Epilepsia. 36:1995;612-626.
173. Braestrup C., Nielsen E. B. (R)-N-(4,4-bis(3-methyl-2-thienyl)but-3-en-l-yl)nipecotic acid binds with high affinity to the brain GABA uptake carrier. J Neurochem. 54:1990;639-664.
174. Giardina W. J. Anticonvulsant action of tiagabine, a new GABA-uptake inhibitor. J Epilepsy. 76:1994;161-166.
175. Nielsen E. B., Suzdak P. D. Characterisation of tiagabine (NO-328), a new potent and selective GABA uptake inhibitor. Eur J Pharmacol. 196:1991;257-266.
176. Faingold C. L., Randall M. E. Blockade of GABA uptake with tiagabine inhibits audiogenic seizures and reduces neuronal firing in the inferior colliculus of the genetically epilepsy-prone rat. Exp Neurol. 126:1994;225-232.
177. Mengel H. Tiagabine. Epilepsia. 35 (Suppl. 5):1994;S81-S84.
178. Bop B. A., Nequist G. E. Role of the cytochrome P450 3A subfamily in the metabolism of [14C] tiagabine by human hepatic microsomes. Epilepsia. 36 (Suppl. 2):1995a;S159.
179. Gustavson L. E., Mengel H. B. Pharmacokinetics of tiagabine, a gamma-aminobutyric acid-uptake inhibitor, in healthy subjects after single and multiple doses. Epilepsia. 36:1995;605-611.
180. Lau A. H., Gustavson L. E. Pharmacokinetics and safety of tiagabine in subjects with various degrees of hepatic function. Epilepsia. 38:1997;445-451.
181. Cato A., Qian J. X. Pharmacokinetics and safety of tiagabine in subjects with various degrees of renal function. Epilepsia. 36 (suppl 3):1995;S159.
182. Gustavson L. E., Boellner S. W. A single-dose study to define tiagabine pharmacokinetics in pediatric patients with complex partial seizures. Neurology. 48:1997;1032-1037.
183. Uthman B. M., Rowan A. J. Tiagabine for complex partial seizures: a randomized, add-on, dose-response trial. Epilepsia. 1997.
184. Sachdeo R. C., Leroy R. F. Tiagabine therapy for complex partial seizures. Arch Neurol. 54:1997;595-601.
185. Ben-Menachem E. International experience with tiagabine add-on therapy. Epilepsia. 36 (Suppl. 6):1995;S14-S21.
186. Schachter S. C. tiagabine monotherapy in the treatment of partial epilepsy. Epilepsia. 36 (suppl 6):1995;S2-S6.
187. Uldall P., Bulteau C. Single-blind study of safety, tolerability, and preliminary efficacy of tiagabine as adjunctive treatment of children with epilepsy. Epilepsia. 36 (Suppl. 3):1995;S147-S148.
188. Schachter S. C. Therapeutic choices and decisions. Presented at the 22nd International Epilepsy Congress Satellite Symposium, Dublin, June 30, 1997.
189. Brodie M. J. A monotherapy approach with tiagabine. Presented at the 22nd International Epilepsy Congress Satellite Symposium, Dublin, June 30, 1997.
190. Leppik I. E. Tiagabine: the safety landscape. Epilepsia. 36 (Suppl. 6):1995;S10-S13.
191. Dodrill C. B., Arnett J. L. Cognitive and quality of life effects of differing dosages of tiagabine in epilepsy. Neurology. 48:1997;1025-1031.
192. Beran, R. G. Currie, J. Sandbach, J. Plunkett, M. Visual field restriction with new antiepileptic medication. International Epilepsy Congress, 1998 Warsaw June 1998 abstract.
193. Masuda Y., Karasawa T., Shiraishi Y., Hori M., Yoshida K., Shimizu M. 3-Sulfamoylmethyl-1,2-benzisoxazole, a new type of anticonvulsant drug. Pharmacological profile. Arzneimittelforsch. 30:1980;477-483.
194. Ito T., Hori M., Masuda Y., Yoshida K., Shimizu M. 3-Sulfamoylmethyl-1,2-benzisoxazole, a new type of anticonvulsant drug. Electroencephalographic profile. Arzneimittelforsch. 30:1980;603-609.
195. Wada Y., Hasegawa H., Okuda H., Yamaguchi N. Anticonvulsant effects of zonisamide and phenytoin on seizure activity of the feline visual cortex. Brain Dev. 12:1991;206-210.
196. Ito T., Hori M., Kadokawa T. Effects of zonisamide (AD-810) on tungstic acid gel-induced thalamic generalized seizures and conjugated estrogen-induced cortical spike-wave discharges in cats. Epilepsia. 27:1986;367-374.
197. Suzuki S., Kawakami K., Nishimura S. Zonisamide blocks T-type calcium channel in cultured neurons of rat cerebral cortex. Epilepsy Res. 12:1992;21-27.
198. Page J. G., Kochak G. M., Polvino W. J., Buchanan R. A. Multiple dose zonisamide metabolism. Epilepsia. 37 (Suppl 5):1996;172.
199. 14C]zonisamide in rat brain. Epilepsy Res. 17:1994;223-236.
200. Seino M., Naruto S., Ito T., Miyazaki H. Other antiepileptic drugs. Levy R. H., Mattson R. H., Meldrum B. S. Antiepileptic drugs, 4th edn. 1995;1011 Raven Press, New York.
201. Stiff D. D., Zemaitis M. A. Metabolism of the anticonvulsant agent zonisamide in the rat. Drug Metab Dispos. 18:1990;888-894.
202. Nakasa H., Komiya M., Ohmori s, Rikihisa T., Kitada M. Rat liver microsomal cytochrome P-450 responsible for reductive metabolism of zonisamide. Drug Metab Dispos. 21:1993a;777-781.
203. 14C]-methyl)-1,2-benzisoxazole (AD-810) in rats, dogs and monkeys and of AD-810 in man. Arzneimittelforsch. 33:1983;961-968.
204. Sackellares J. C., Donofrio P. D., Wagner J. G., Abou-Khalil B., Berent S., AAsved-Hoyt K. Pilot study of zonisamide (1,2-benzisoxazole-3-methanesulfonamide) in patients with refractory partial seizures. Epilepsia. 26:1985;206-211.
205. Wilder, B. J. Ramsay, R. E. Guterman, A. A double-blind multicenter placebo-controlled study of the efficacy and safety of zonisamide in the treatment of complex partial seizures in medically refractory patients. Internal report of Dainippon Pharmaceutical Co, Ltd.
206. Schmidt D., Jacob R., Loiseau P. Zonisamide for add-on treatment of refractory partial epilepsy: a European double blind trial. Epilepsy Res. 15:1993;67-73.
207. Leppik I. E., Willmore L. J., Homan R. W. Efficacy and safety of zonisamide: results of a multicenter study. Epilepsy Res. 14:1993;165-173.
208. Browne T. R., Leppik I. E., Penry J. K., Dean C., Buchanan R. A. Zonisamide efficacy in long term studies. Epilepsia (in press). 1997.
209. Kyllerman M., Ben-Menachem E. Long-term treatment of progressive myoclonic epilepsy syndromes with zonisamide and n-acetylcysteine. Epilepsia. 37 (Suppl 5):1996;172.
210. Yamatogi Y., Ohtahara S. Current topics of treatment. In: Ohtahara S, Roger J (eds). Proceedings of the international symposium, new trends in pediatric epileptology. Okayama University Medical School, 1991;136-148.
211. Seino M., Miyazaki H., Ito T. Zonisamide. Pisani F., Perucca E., Avanzini G., Richens A. New antiepileptic drugs (Epilepsy Res Suppl 3). 1991;169 Elsevier, New York.
212. Padgett C. S., Bergen D. C., French J. A., Buchanan R. A. Renal calculi associated with zonisamide. Epilepsia. 37 [Suppl 5]:1997;173.
213. Kondo T., Kaneko S., Amano Y., Egawa I. Preliminary report on teratogenic effects of zonisamide in the offspring of treated women with epilepsy. Epilepsia. 37:1996;1242-1244.
214. Wamil A. W., Portet C. H. Oxcarbazepine and its monohydroxy metabolite limit action potential firing by mouse central neurons in cell culture. Epilepsia. 32:1991;65-66.
215. Schmutz M., Brugger F., Gentsch C., McLean M. J., Olbe H. R. Oxcarbazepine: preclinical anticonvulsant profile and putative mechanisms of action. Epilepsia. 35 [Suppl 5]:1994;S47-S50.
216. Stefani A., Pisani A., DeMurtas M., Mercuri N. B., Marciana M. G., Calabresi P. Action of GP 47779, the active metabolite of oxcarbazepine, on the corticostriatal system. II. Modulation of high-voltage-activated calcium currents. Epilepsia. 36:1995;997-1002.
217. Dam M., Ekberg R., Loyning Y., Waltimo O., Jakoben K. A double-blind study comparing oxcarbazepine and carbamazepine in patients with newly diagnosed, previously untreated epilepsy. Epilepsy Res. 3:1989;70-76.
218. Bill P. A., Vigonius U., Pohlmann H., Guerrio C. A. M., Kochen S., Saffer D., Moore A. A double-blind controlled clinical trial of oxcarbazepine versus phenytoin in adults with previously untreated epilepsy. Epilepsy Res. 27:1997;195-204.
219. Guerreiro M. M., Vigonius U., Pohlmann H., de Manreza M. L. G., Fejerman N., Antonick S. A., Moore A. A double-blind controlled clinical trial of oxcarbazepine versus phenytoin in children and adolescents with epilepsy. Epilepsy Res. 27:1997;205-213.
220. Schachter S. C., Vazquez B. Oxcarbazepine: a double-blind, placebo-controlled, monotherapy trial in patients with epilepsy after presurgical evaluation of refractory partial seizxures. Neurology (submitted). 1997.
221. Houtkooper M. A., Lammertsma A., Meyer J. W., Goedhart D. M., Meinardi H., van Oorschat C. A., Blom G. F., Hoppener R. J., Hulsman J. A. Oxcarbazepine (GP 47680) - a possible alternative to carbamazepine? Epilepsia. 28:1987;693-698.
222. Van Parys J. A. P., Meinardi H. Survey of 260 epileptic patients treated with oxcarbazepine (Trileptal) on a named-patient basis. Epilepsy Res. 19:1994;79-85.
223. Klosterkov Jensen P., Saano V., Haring P., Svenstrup B., Menge G. P. Possible interaction between oxcarbazepine and an oral contraceptive. Epilepsia. 33:1992;1149-1152.
224. Sonnen A. E. H. Oxcarbazepine and oral contraceptives. Acta Neurol Scand 82. [Suppl 133]:1990;37.
225. Friis M. L., Kristensen O., Boas J., Dalby M., Deth S. H., Gram L., Mikkelsen M., Pedersen B., Sabers A., Worm-Pedersen J. Therapeutic experiences with 947 epileptic out-patients in oxcarbazepine treatment. Acta Neurol Scand. 87:1993;224-227.
226. Jensen, N. O. Oxcarbazepine in patients hypersensitive to carbamazepine. 16th Epilepsy International Congress, Hamburg.
227. Van Amelsvoort T., Bakshi R., Devauz C. B., Schwabe S. Hyponatremia associated with carbamazepine and oxcarbazepine therapy: a review. Epilepsia. 35:1994;181-188.
228. Neilsen O. A., Johannessen A. C., Bardrum B. Oxcarbazepine-induced hyponatremia, a cross-sectional study. Epilepsy Res. 2:1988;269-271.
229. Cornford E. A., Young D., Paxton J. A., Sofia R. D. Blood-brain barrier penetration of felbamate. Epilepsia. 33:1992;944-955.
230. Perhach J. L., Weliky I., Newton J. J., Sofia R. D., Romayshyn W. M., Arndt W. F. jr. Felbamate. Porter R. J., Meldrum B. S. New anticonvulsant drugs. 1986;117-124 Libby, London.
231. Cornford E. M., Truong H. V., Sofie R. D., Kucharczyk N. Distribution of felbamate in brain. Epilepsia. 37:1996;15-18.
232. Palmer K. J., McTavish D. Felbamate: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in epilepsy. Drugs. 45:1993;1041-1065.
233. Areceptors. Ann Neurol. 35:1994;229-234.
234. Areceptor system. Epilepsia. 32:1991;389-391.
235. White H. S., Wolf H. H., Swinyard E. A., Skeen G. A., Sofia R. D. A neuropharmacological evaluation of felbamate as a novel anticonvulsant. Epilepsia. 33:1992;564-572.
236. De Sarro G., Ongini E., Bertorelli R., Aguglia U., De Sarro A. Excitatory amino acid neurotransmission through both NMDA and non-NMDA receptors involved in the anticonvulsant activity of felbamate in DBA/2 mice. Eur J Pharmacol. 262:1994;11-19.
237. Pugliese A. M., Passani M. B., Pepeu G., Corradetti R. Felbamate decreases synaptic transmission in the CA1 region of rat hippocampal slices. J Pharmacol Exp Ther. 279:1996;1100-1108.
238. Domenici M. R., Marinelli S., Sagratella S. Effects of felbamate, kynurenic acid derivatives and NMDA antagonists on in vitro kainate-induced epileptiform activity. Life Sci. 58:1996;PL391-396.
239. McCabe R. T., Wasterlain C. G., Kucharcyzk N., Sofia R. W., Vogel J. R. Evidence for anticonvulsant and neuroprotectant action of felbamate mediated by strychnine-insensitive glycine receptors. J Pharmacol Exp Ther. 264:1993;1248-1252.
240. Kanthasamy A. G., Matsumoto R. R., Gunasekar P. G., Trunong D. D. Excitoprotective effect of felbamate in cultured cortical neurons. Brain Res. 705:1995;97-104.
241. Imamura Y., Bennett G. J. Felbamate relieves several abnormal pain sensations in rats with an experimental peripheral neuropathy. J Pharmacol Exp Ther. 275:1995;177-182.
242. Cheshire W. P. Felbamate relieved trigeminal neuralgia. Clin J Pain. 11:1995;139-142.
243. Wilensky A. J., Friel P. N., Ojemann L. M., Kupferberg H. J., Levy R. H. Pharmacokinetics of W-554 (ADD 03055) in epileptic patients. Epilepsia. 26:1985;602-606.
244. Richens A., Banfield C. R., Salfi M., Nomeir A., Lin C. C., Jensen P., Affrime M. B., Glue P. Single and multiple dose pharmacokinetics of felbamate in the elderly. Br J Clin Pharmacol. 44:1997;129-134.
245. Li L. M., Nashef L., Moriarty J., Duncan J. S., Sandler J. W. Felbamate as add-on therapy. Eur Neurol. 36:1996;146-148.
246. Glue P., Sulowicz W., Colucci R., Banfield C., Pai S., Lin C., Affrime M. B. Single-dose pharmacokinetics of felbamate in patients with renal dysfunction. Br J Clin Pharmacol. 44:1997;91-93.
247. Albani F., Theodore W. H., Washington P. Effect of felbamate on plasma levels of carbamazepine and its metabolites. Epilepsia. 32:1991;130-132.
248. Fuerst R. H., Graves N. M., Leppik I. E., Brundage R. C., Holmes G. B., Remmel R. P. Felbamate increases phenytoin but decreases carbamazepine concentrations. Epilepsia. 29:1988;488-491.
249. Graves N. M., Holmes G. B., Fuerst R. H., Leppik I. E. Effect of felbamate on phenytoin and carbamazepine serum concentrations. Epilepsia. 30:1989;225-229.
250. Leppik I. E., Dreifuss F. E., Pledger G. W. Felbamate for partial seizures; results of a controlled clinical trial. Neurology. 41:1991;1785-1789.
251. Wagner M. L., Graves N. M., Marienau K., Holmes G. B., Remmel R. P., Leppik I. E. Discontinuation of phenytoin and carbamazepine in patients receiving felbamate. Epilepsia. 32:1991;398-406.
252. Reidenberg P., Glue P., Banfield C. R., Colucci R. D., Meehan J. W., Radwanski E., Mojavarian P., Lin C. C., Nezamis J., Guillaume M. Effects of felbamate on the pharmacokinetics of phenobarbital. Clin Pharmacol Ther. 58:1995;279-287.
253. Saano V., Glue P., Banfield C. R., Reidenberg P., Colucci R. D., Meehan J. W., Haring P., Radwanski E., Nomeir A., Lin C. C. Effects of felbamate on the pharmacokinetics of a low-dose combination oral contraceptive. Clin Pharmacol Ther. 58:1995;523-531.
254. Theodore W. H., Raubertas R., Porter R. J. Felbamate: a clinical trial for complex partial seizures. Epilepsia. 32:1991;392-397.
255. Devinsky O., Faught R. E., Wilder B. J., Kanner A. M., Kamin M., Kramer I. D., Rosenberg A. Efficacy of felbamate monotherapy in patients undergoing presurgical evaluation of partial seizures. Epilepsy Res. 20:1995;241-246.
256. Bourgeois B., Leppik I. E., Sackellares J. C. Felbamate: a double-blind controlled trial in patients undergoing presurgincal evaluation of partial seizures. Neurology. 43:1993;693-696.
257. Faught E., Sachdeo R. C., Remler M. P. Felbamate monotherapy for partial-onset seizures: an active control trial. Neurology. 43:1993;688-692.
258. Sachdeo R., Kramer L. D., Rosenberg A., Sachdeo S. Felbamate monotherapy: controlled trial in patients with partial onset seizures. Ann Neurol. 32:1992;386-392.
259. Jensen P. K. Felbamate in the treatment of refractory partial onset seizures. Epilepsia. 34 [Suppl 7]:1993;S25-S29.
260. Avanzini G., Canger R., Dalla Bernadina B., Vigevano F. Felbamate in therapy-resistant epilepsy: an Italian experience. Epilepsy Res. 25:1996;249-255.
261. Carmant L., Holmes G. L., Sawyer S., Rifai N., Anderson J., Mikati M. A. Efficacy of felbamate in therapy for partial epilepsy in children. J Pediatr. 125:1994;481-486.
262. N Engl J Med. 328:1993;29-33.
263. Oletsky H., Kelley K., Stertz B., Reeves-Tyer P., Flamini R., Malow B., Theodore W. H. The efficacy of felbamate as add-on therapy to valproic acid in the Lennox-Gastaut Syndrome. Epilepsia. 37 [Suppl 5]:1996;155.
264. Pellock J. M., Brodie M. J. Felbamate: 1997 Update. Epilepsia. 38:1997;1261-1264.
265. O'Neill M. G., Perdun C. S., Wilson M. B., McGown S. T., Patel S. Felbamate-associated fatal acute hepatic necrosis. Neurology. 46:1996;1457-1459.
266. Jensen P. K. Felbamate in the treatment of Lennox-Gastaut Syndrome. Epilepsia. 35 [Suppl 5]:1994;S54-S57.
267. Ketter T. A., Malow B. A., Flamini R., Ko D., White S. R., Post R. M., Theodore W. H. Felbamate monotherapy has stimulant-like effects in patients with epilepsy. Epilepsy Res. 23:1996;129-137.
268. McConnell H., Snyder P. J., Duffy J. D., Weilburg J., Valeriano J., Brillman J., Cress K., Cavalier J. Neuropsychiatric side effects related to treatment with felbamate. J Neuropsychiatry Clin Neurosci. 8:1996;341-346.
269. Ettinger A. B., Jandorf L., Berdia A., Andriola M. R., Krupp L. B., Weisbrot D. M. Felbamate-induced headache. Epilepsia. 37:1996;503-505.
270. Hahn M., Gildmeister O. S., Krauss G. L., Pepe J. A., Lambrecht R. W., Donohue S., Bonkovski H. L. Effects of new anticonvulsant medications on porphyrin synthesis in cultured liver cells: potential implications for patients with acute porphyria. Neurology. 1997;49-97-106.